Carla M. L. van Herpen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carla M. L. van Herpen has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Gosse J. Adema
Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
3 shared publications- Mathijs P. Hendriks
Department of Medical Oncology, Northwest Clinics, Alkmaar, The Netherlands
3 shared publications - Ann Hoeben
Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, Netherlands
2 shared publications - Bas Kreike
Institute for Radiation Oncology Arnhem, Arnhem, The Netherlands
2 shared publications Chantal Driessen
Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
2 shared publications- Chantal Maria Leonarda Driessen
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 6075
Cost-effectiveness of prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).
6075 Background: Recently, we reported about a prospective randomized study (PANTAP-study) investigating the effect of prophylactic antibiotics in LAHNC pts treated with CRT. We did not show a reduction in pneumonias, but did find a significant decrease in the number of hospitalizations. Detailed quality of life (QoL) results have been reported elsewhere. Now we present the results of the cost-effectiveness analysis. Methods: A multicenter study was performed in LAHNC pts treated with CRT, i.e.cisplatin weekly or 3-weekly combined with radiotherapy for 42 or 49 days. The standard treatment group (STG) received no prophylactic antibiotics; the intervention group (IG) received prophylactic antibiotics, i.e. amoxicillin/clavulanic acid, from day 29 until 14 days after completion of CRT. QoL questionnaires, including EQ-5D, QLQ-C30, EORTC Head&Neck35 and PSSHN, were taken before start of CRT, before start of antibiotics, at the end of CRT and at the end of follow up. Costs of hospitalization, prophylactic antibiotics, pain medication and anti-emetics were taken into account for the cost-effectiveness analysis. Results: A total of 94 pts were randomized; 48 pts to the STG and 47 pts to the IG. Between the STG and IG we found a difference per patient in costs of hospitalization of €2076 and €682 (p = 0.03), respectively, but not in the costs for pain medication per patient €78 and €46, respectively, (p = 0.382). The total costs of hospitalization in combination with prophylactic antibiotics, pain medication and anti-emetics were €2462 and €1037 (p = 0.046) in the STG and IG respectively, leading to a difference in total costs per patient of €1425 in favor of the IG. There were no significant differences in QoL between the groups. Conclusions: Prophylactic antibiotics during CRT for LAHNC did not reduce the rate of pneumonias, but reduced the number of hospitalizations in the IG, which led to a significant reduction in costs. Given the lack of adverse clinical effects, the same QoL, the cost savings and the impact of costs of hospitalization on health care globally, we recommend the use of prophylactic antibiotics in LAHNC pts receiving CRT. Clinical trial information: NCT01598402.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 6075
Cost-effectiveness of prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).
6075 Background: Recently, we reported about a prospective randomized study (PANTAP-study) investigating the effect of prophylactic antibiotics in LAHNC pts treated with CRT. We did not show a reduction in pneumonias, but did find a significant decrease in the number of hospitalizations. Detailed quality of life (QoL) results have been reported elsewhere. Now we present the results of the cost-effectiveness analysis. Methods: A multicenter study was performed in LAHNC pts treated with CRT, i.e.cisplatin weekly or 3-weekly combined with radiotherapy for 42 or 49 days. The standard treatment group (STG) received no prophylactic antibiotics; the intervention group (IG) received prophylactic antibiotics, i.e. amoxicillin/clavulanic acid, from day 29 until 14 days after completion of CRT. QoL questionnaires, including EQ-5D, QLQ-C30, EORTC Head&Neck35 and PSSHN, were taken before start of CRT, before start of antibiotics, at the end of CRT and at the end of follow up. Costs of hospitalization, prophylactic antibiotics, pain medication and anti-emetics were taken into account for the cost-effectiveness analysis. Results: A total of 94 pts were randomized; 48 pts to the STG and 47 pts to the IG. Between the STG and IG we found a difference per patient in costs of hospitalization of €2076 and €682 (p = 0.03), respectively, but not in the costs for pain medication per patient €78 and €46, respectively, (p = 0.382). The total costs of hospitalization in combination with prophylactic antibiotics, pain medication and anti-emetics were €2462 and €1037 (p = 0.046) in the STG and IG respectively, leading to a difference in total costs per patient of €1425 in favor of the IG. There were no significant differences in QoL between the groups. Conclusions: Prophylactic antibiotics during CRT for LAHNC did not reduce the rate of pneumonias, but reduced the number of hospitalizations in the IG, which led to a significant reduction in costs. Given the lack of adverse clinical effects, the same QoL, the cost savings and the impact of costs of hospitalization on health care globally, we recommend the use of prophylactic antibiotics in LAHNC pts receiving CRT. Clinical trial information: NCT01598402.
- 1 July 2016
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 27 (6) , 576-579
A successful approach to overcome imatinib-induced skin toxicity in a GIST patient
Since the introduction of tyrosine kinase inhibitors in gastrointestinal stromal tumor patients, the median survival of patients has increased from less than 1 to more than 5 years. The chronic use of a tyrosine kinase inhibitor has an impact on quality of life because of its toxicity. Adequate supportive therapy is therefore important. We describe a female patient with a metastatic gastrointestinal stromal tumor. During treatment with the c-KIT inhibitor imatinib, she developed severe therapy-limiting skin toxicity. After several different supportive attempts, the combination of doxycycline and clemastine proved to be the solution, enabling successful chronic treatment with imatinib. Chronic use of doxycycline and clemastine is useful in the management of skin toxicity caused by c-KIT inhibitors, enabling the needed long-term use of these kind of anticancer drugs without hampering the quality of life.
- 1 July 2016
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 27 (6) , 576-579
A successful approach to overcome imatinib-induced skin toxicity in a GIST patient
Since the introduction of tyrosine kinase inhibitors in gastrointestinal stromal tumor patients, the median survival of patients has increased from less than 1 to more than 5 years. The chronic use of a tyrosine kinase inhibitor has an impact on quality of life because of its toxicity. Adequate supportive therapy is therefore important. We describe a female patient with a metastatic gastrointestinal stromal tumor. During treatment with the c-KIT inhibitor imatinib, she developed severe therapy-limiting skin toxicity. After several different supportive attempts, the combination of doxycycline and clemastine proved to be the solution, enabling successful chronic treatment with imatinib. Chronic use of doxycycline and clemastine is useful in the management of skin toxicity caused by c-KIT inhibitors, enabling the needed long-term use of these kind of anticancer drugs without hampering the quality of life.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11040
Food intervention to make therapy with pazopanib more patient-friendly and affordable.
11040 Background: Pazopanib has been registered for advanced soft tissue sarcoma (STS) and metastatic renal cell carcinoma (mRCC) and is used at a fixed oral dose of 800 mg taken fasted. However, ingesting pazopanib with food is a more patient friendly approach. Moreover, the occurrence of gastro-intestinal adverse events, a well-known side effect of pazopanib, could potentially be reduced when taken with food. Finally, a food intervention resulting in a better absorption and similar exposure to pazopanib, can lead to a reduced dose, which could significantly impact costs. The aim of the study was to establish the bio-equivalent dose of pazopanib taken with a continental breakfast compared to the standard intake of 800mg OD in fasted state. Methods: in this phase I cross-over multi-center study pazopanib pharmacokinetics (PK) were evaluated in STS and mRCC patients treated with 800 mg pazopanib in a fasted state, followed by 600 mg ingested with a continental breakfast based on PK evaluation. After both periods of 14 days, pazopanib plasma exposure was measured. Bioequivalence was assumed when the GMR (fed/fasted) of the AUC0-24h and Cmax and their 90% confidence interval (CI) were within the range of 0.8 and 1.25. Results: 19 patients were enrolled into the study, of whom 16 were eligible for PK analysis. GMR (fed/fasted) AUC0-24h was 1.09 (CI 1.02-1.17) and GMR Cmax was 1.12 (CI 1.04-1.20). 92% of our patients continued to use pazopanib with food. Conclusions: By a simple food intervention a 25% reduced dose of pazopanib results in an exposure, which is bioequivalent to 800 mg OD taken fasted. Most patients in this study choose to continue using pazopanib with food, emphasizing the patient friendliness of this approach for patients with STS and mRCC. Lastly, this approach may contribute to keep oncolytic therapy, such as pazopanib, more affordable and thus probably more available to all patients. Clinical trial information: NCT02138526.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11040
Food intervention to make therapy with pazopanib more patient-friendly and affordable.
11040 Background: Pazopanib has been registered for advanced soft tissue sarcoma (STS) and metastatic renal cell carcinoma (mRCC) and is used at a fixed oral dose of 800 mg taken fasted. However, ingesting pazopanib with food is a more patient friendly approach. Moreover, the occurrence of gastro-intestinal adverse events, a well-known side effect of pazopanib, could potentially be reduced when taken with food. Finally, a food intervention resulting in a better absorption and similar exposure to pazopanib, can lead to a reduced dose, which could significantly impact costs. The aim of the study was to establish the bio-equivalent dose of pazopanib taken with a continental breakfast compared to the standard intake of 800mg OD in fasted state. Methods: in this phase I cross-over multi-center study pazopanib pharmacokinetics (PK) were evaluated in STS and mRCC patients treated with 800 mg pazopanib in a fasted state, followed by 600 mg ingested with a continental breakfast based on PK evaluation. After both periods of 14 days, pazopanib plasma exposure was measured. Bioequivalence was assumed when the GMR (fed/fasted) of the AUC0-24h and Cmax and their 90% confidence interval (CI) were within the range of 0.8 and 1.25. Results: 19 patients were enrolled into the study, of whom 16 were eligible for PK analysis. GMR (fed/fasted) AUC0-24h was 1.09 (CI 1.02-1.17) and GMR Cmax was 1.12 (CI 1.04-1.20). 92% of our patients continued to use pazopanib with food. Conclusions: By a simple food intervention a 25% reduced dose of pazopanib results in an exposure, which is bioequivalent to 800 mg OD taken fasted. Most patients in this study choose to continue using pazopanib with food, emphasizing the patient friendliness of this approach for patients with STS and mRCC. Lastly, this approach may contribute to keep oncolytic therapy, such as pazopanib, more affordable and thus probably more available to all patients. Clinical trial information: NCT02138526.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6079
Prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).
6079 Background: Platinum-based CRT is the treatment of choice for LAHNC, but induces a high rate of acute toxicity, including dysphagia and aspiration pneumonia. Aspiration pneumonia often requires hospitalization and negatively influences quality of life (QoL). We hypothesized that prophylactic antibiotics during CRT in LAHNC patients (pts) can prevent pneumonia and hospital admissions. Methods: A multicenter randomized trial was performed. The standard treatment group (STG) received standard care; the intervention group (IG) received prophylactic amoxicillin/clavulanic acid from day 29 until 14 days after completion of CRT. LAHNC pts treated with CRT were registered before start and randomized between day 21-28, unless they received antibiotics 14 days before planned randomization. The primary objective was to measure a reduction in the rate of pneumonias. A confirmed pneumonia was defined as a previously non-existing infiltrate on chest X-ray or ≥ 3 of the following features: sustained fever, rales or rhonchi on chest auscultation, sputum with substantial leukocytes or sputum culture showing a pathogen. A suspected pneumonia was defined as 2 of these features. Results: A total of 106 pts were registered, of which 94 pts were randomized: 48 pts were allocated to the STG and 46 pts to the IG. Pts were equally randomized by minimization for smoking, COPD status, HPV status in oropharyngeal cancer, degree of weight loss, primary tumor site, participating centre and tube feeding at time of randomization. A confirmed or suspected pneumonia during CRT and follow up till 3.5 months was observed in 20 (41.7%) of 48 pts in the STG, and 20 (43.5%) of 46 pts in the IG, respectively (P = 0.56). Hospitalization for any cause (i.e., fever, dehydration, mucositis or pneumonia), was necessary in 17 of 48 pts (35.4%) in the STG versus 9 of 46 pts (19.6%) in the IG (P = .08). Conclusions: Prophylactic antibiotics during CRT for LAHNC did not reduce the rate of pneumonias. However, there is a trend towards a reduced rate of hospitalizations, which potentially may lead to a better QoL and reduction in costs. Currently, further microbiological and cost-effectiveness analyses are being performed. Clinical trial information: NCT01598402.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6079
Prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).
6079 Background: Platinum-based CRT is the treatment of choice for LAHNC, but induces a high rate of acute toxicity, including dysphagia and aspiration pneumonia. Aspiration pneumonia often requires hospitalization and negatively influences quality of life (QoL). We hypothesized that prophylactic antibiotics during CRT in LAHNC patients (pts) can prevent pneumonia and hospital admissions. Methods: A multicenter randomized trial was performed. The standard treatment group (STG) received standard care; the intervention group (IG) received prophylactic amoxicillin/clavulanic acid from day 29 until 14 days after completion of CRT. LAHNC pts treated with CRT were registered before start and randomized between day 21-28, unless they received antibiotics 14 days before planned randomization. The primary objective was to measure a reduction in the rate of pneumonias. A confirmed pneumonia was defined as a previously non-existing infiltrate on chest X-ray or ≥ 3 of the following features: sustained fever, rales or rhonchi on chest auscultation, sputum with substantial leukocytes or sputum culture showing a pathogen. A suspected pneumonia was defined as 2 of these features. Results: A total of 106 pts were registered, of which 94 pts were randomized: 48 pts were allocated to the STG and 46 pts to the IG. Pts were equally randomized by minimization for smoking, COPD status, HPV status in oropharyngeal cancer, degree of weight loss, primary tumor site, participating centre and tube feeding at time of randomization. A confirmed or suspected pneumonia during CRT and follow up till 3.5 months was observed in 20 (41.7%) of 48 pts in the STG, and 20 (43.5%) of 46 pts in the IG, respectively (P = 0.56). Hospitalization for any cause (i.e., fever, dehydration, mucositis or pneumonia), was necessary in 17 of 48 pts (35.4%) in the STG versus 9 of 46 pts (19.6%) in the IG (P = .08). Conclusions: Prophylactic antibiotics during CRT for LAHNC did not reduce the rate of pneumonias. However, there is a trend towards a reduced rate of hospitalizations, which potentially may lead to a better QoL and reduction in costs. Currently, further microbiological and cost-effectiveness analyses are being performed. Clinical trial information: NCT01598402.
- 1 October 2015
- Vol. 35 (10) , 5601-6
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
To gain greater insight into the biological mechanisms occurring shortly after discontinuation of VEGFR TKIs treatment because of progressive disease (PD). Sixteen patients with PD during treatment with sorafenib or sunitinib were randomized to either directly stop the VEGFR TKI or to continue for another two weeks. At baseline (i.e. at the moment of PD) and after two weeks FDG-PET/CT, functional-MRI and blood biomarkers of disease were evaluated. A statistically significant difference in median change from baseline to two weeks later in K(trans) and LDH levels was observed between patients who directly stopped versus those who continued treatment (1.6 s(-1) versus -1.1s(-1), p=0.03; -73.0 U/L versus 52.0 U/L, p=0.008; respectively). There were no further differences between groups. Two weeks after discontinuation of VEGFR TKIs in mRCC because of PD, a rise in K(trans) accompanied by a decrease in LDH indicates an increase in tumor vascularization. This implies that at the moment of PD the effect of VEGFR TKIs is not completely exhausted.
- 1 October 2015
- Vol. 35 (10) , 5601-6
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
To gain greater insight into the biological mechanisms occurring shortly after discontinuation of VEGFR TKIs treatment because of progressive disease (PD). Sixteen patients with PD during treatment with sorafenib or sunitinib were randomized to either directly stop the VEGFR TKI or to continue for another two weeks. At baseline (i.e. at the moment of PD) and after two weeks FDG-PET/CT, functional-MRI and blood biomarkers of disease were evaluated. A statistically significant difference in median change from baseline to two weeks later in K(trans) and LDH levels was observed between patients who directly stopped versus those who continued treatment (1.6 s(-1) versus -1.1s(-1), p=0.03; -73.0 U/L versus 52.0 U/L, p=0.008; respectively). There were no further differences between groups. Two weeks after discontinuation of VEGFR TKIs in mRCC because of PD, a rise in K(trans) accompanied by a decrease in LDH indicates an increase in tumor vascularization. This implies that at the moment of PD the effect of VEGFR TKIs is not completely exhausted.
- 1 February 2013
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 24 (2) , 204-211
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment
Vascular endothelial growth factor (VEGF) signalling plays a key role in tumour angiogenesis. Cediranib (AZD2171) is a small-molecule VEGF signalling inhibitor with potent activity against all three VEGF receptors. In this phase I, open-label, parallel-group study, adults with advanced solid tumours received a single 45 mg dose of cediranib, followed by 30 mg continuous once-daily oral dosing for 21 days after a 7-day washout period (clinicaltrials.gov identifier NCT00621725). The primary objective was to compare the single-dose pharmacokinetics (PK) of cediranib in patients with different levels of hepatic impairment classified according to the bilirubin level. Safety, tolerability, multiple-dose PK and PK stratified according to the Child-Pugh criteria were also assessed. Thirty patients received cediranib: 18 with normal-mild hepatic impairment and 12 with moderate hepatic impairment. Single-dose PK parameters were similar between the group with normal-mild hepatic impairment and the group with moderate hepatic impairment [ratio of geometric least square means: area under the curve (AUC) 1.12, 90% confidence interval (CI) 0.77-1.61; Cmax 0.95, 90% CI 0.69-1.31]. Hepatic impairment did not influence PK results in multiple dosing. After continuous once-daily dosing, the geometric least square means ratio was 0.72 (90% CI 0.51-1.03) for AUCSS and 0.67 (90% CI 0.47-0.94) for CSS,max. Similar results were obtained when patients were classified for hepatic impairment according to the Child-Pugh criteria. There was no clear difference in the incidence or the severity of adverse events between hepatic impairment groups. Moderate hepatic impairment does not appear to affect the PK profile or the tolerability of cediranib. Dose adjustments are not necessary in this patient population.
- 1 February 2013
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 24 (2) , 204-211
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment
Vascular endothelial growth factor (VEGF) signalling plays a key role in tumour angiogenesis. Cediranib (AZD2171) is a small-molecule VEGF signalling inhibitor with potent activity against all three VEGF receptors. In this phase I, open-label, parallel-group study, adults with advanced solid tumours received a single 45 mg dose of cediranib, followed by 30 mg continuous once-daily oral dosing for 21 days after a 7-day washout period (clinicaltrials.gov identifier NCT00621725). The primary objective was to compare the single-dose pharmacokinetics (PK) of cediranib in patients with different levels of hepatic impairment classified according to the bilirubin level. Safety, tolerability, multiple-dose PK and PK stratified according to the Child-Pugh criteria were also assessed. Thirty patients received cediranib: 18 with normal-mild hepatic impairment and 12 with moderate hepatic impairment. Single-dose PK parameters were similar between the group with normal-mild hepatic impairment and the group with moderate hepatic impairment [ratio of geometric least square means: area under the curve (AUC) 1.12, 90% confidence interval (CI) 0.77-1.61; Cmax 0.95, 90% CI 0.69-1.31]. Hepatic impairment did not influence PK results in multiple dosing. After continuous once-daily dosing, the geometric least square means ratio was 0.72 (90% CI 0.51-1.03) for AUCSS and 0.67 (90% CI 0.47-0.94) for CSS,max. Similar results were obtained when patients were classified for hepatic impairment according to the Child-Pugh criteria. There was no clear difference in the incidence or the severity of adverse events between hepatic impairment groups. Moderate hepatic impairment does not appear to affect the PK profile or the tolerability of cediranib. Dose adjustments are not necessary in this patient population.
- Open Access
- 17 December 2012
- Published by Springer Nature in BMC Immunology
- Vol. 13 (1) , 71
Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome
Chronic fatigue syndrome (CFS) is a clinical condition characterized by severe and disabling fatigue that is medically unexplained and lasts longer than 6 months. Although it is possible to effectively treat CFS, the nature of the underlying physiology remains unclear. Various studies have sought evidence for an underlying disturbance in immunity. The aim of this study was to compare the humoral and cellular immune responses upon influenza vaccination in CFS patients and healthy controls.
- 17 December 2012
- Published by Springer Nature in BMC Immunology
- Vol. 13 (1) , 71
Open AccessHumoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome
Chronic fatigue syndrome (CFS) is a clinical condition characterized by severe and disabling fatigue that is medically unexplained and lasts longer than 6 months. Although it is possible to effectively treat CFS, the nature of the underlying physiology remains unclear. Various studies have sought evidence for an underlying disturbance in immunity. The aim of this study was to compare the humoral and cellular immune responses upon influenza vaccination in CFS patients and healthy controls.
- 21 August 2012
- Published by Wiley in Head & Neck
- Vol. 35 (8) , E246-E250
Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects
Background: Aggressive fibromatosis (AF) or desmoid tumor of the head and neck region is a rare, usually unresectable, benign soft tissue tumor with locally aggressive behavior.Methods and Results: A 31‐year‐old woman presented with a progressive trismus, a swelling in the retromandibular area, as well as loss of sensibility of the maxillary and mandibular branch of the trigeminal nerve. MRI of the head and neck revealed an infiltrative mass involving the masticator, parapharyngeal, and prevertebral and paravertebral space on the left with intracranial extension through the orbital fissure. After the fifth biopsy, 15 months after presentation, the diagnosis of AF was made. The tumor was unresectable, so intensity‐modulated radiotherapy was given with curative intent using a total dose of 60 Gy in 30 fractions of 2 Gy. After 16 months, she showed progressive disease, for which tamoxifen 40 mg twice daily was started with a good response for 2 years. After that, she started with sorafinib, on which she has stable disease now.Conclusion: The often long delay in proper diagnosis and the treatment challenges of a desmoid tumor are illustrated in this case. Furthermore, this article reviews the literature concerning AF, especially of the head and neck region. Head Neck, 2013
- 21 August 2012
- Published by Wiley in Head & Neck
- Vol. 35 (8) , E246-E250
Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects
Background: Aggressive fibromatosis (AF) or desmoid tumor of the head and neck region is a rare, usually unresectable, benign soft tissue tumor with locally aggressive behavior.Methods and Results: A 31‐year‐old woman presented with a progressive trismus, a swelling in the retromandibular area, as well as loss of sensibility of the maxillary and mandibular branch of the trigeminal nerve. MRI of the head and neck revealed an infiltrative mass involving the masticator, parapharyngeal, and prevertebral and paravertebral space on the left with intracranial extension through the orbital fissure. After the fifth biopsy, 15 months after presentation, the diagnosis of AF was made. The tumor was unresectable, so intensity‐modulated radiotherapy was given with curative intent using a total dose of 60 Gy in 30 fractions of 2 Gy. After 16 months, she showed progressive disease, for which tamoxifen 40 mg twice daily was started with a good response for 2 years. After that, she started with sorafinib, on which she has stable disease now.Conclusion: The often long delay in proper diagnosis and the treatment challenges of a desmoid tumor are illustrated in this case. Furthermore, this article reviews the literature concerning AF, especially of the head and neck region. Head Neck, 2013
- 17 February 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (6) , e17-e18
Cetuximab-induced pneumonitis in head and neck cancer patient
- 17 February 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (6) , e17-e18
Cetuximab-induced pneumonitis in head and neck cancer patient
- Open Access
- 28 September 2010
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (9) , 1362-1368
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
- 28 September 2010
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (9) , 1362-1368
Open AccessA Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours